Arbutus Biopharma
ABUS
72 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 7 closing their positions.
89% more call options, than puts
Call options by funds: $891K | Put options by funds: $472K
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
1% more funds holding
Funds holding: 71 → 72 (+1)
0.6% less ownership
Funds ownership: 43.56% → 42.96% (-0.6%)
7% less capital invested
Capital invested by funds: $92.6M → $86.5M (-$6.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$4.51M |
| 2 |
JP Morgan Chase
New York
|
+$2.94M |
| 3 |
Goldman Sachs
New York
|
+$512K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$113K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.26M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$2.99M |
| 3 |
Morgan Stanley
New York
|
-$459K |
| 4 |
BlackRock
New York
|
-$432K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$359K |
ABUS Hedge Fund Activity: Q1 2019 in Review
72 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2019, worth a combined $86.5M — down 6.6% from $92.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ABUS positions and 7 closed out — a net gain of 1 holder — while 23 added to existing stakes and 18 trimmed.
The largest buyer was RTW Investments, adding an estimated $4.51M. The largest seller was EcoR1 Capital, cutting an estimated $4.26M.
- 72 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2019, up from 71 in Q4 2018.
- Funds reported $86.5M of Arbutus Biopharma stock for Q1 2019, down 6.6% quarter-over-quarter.
- 8 funds opened new Arbutus Biopharma positions in Q1 2019 and 7 closed out, a net change of +1 holder.
- The largest Arbutus Biopharma buyer in Q1 2019 was RTW Investments, an estimated $4.51M added.
- The largest Arbutus Biopharma seller in Q1 2019 was EcoR1 Capital, an estimated $4.26M sold.
Based on aggregated 13F filings for Q1 2019.